Extent and location of tumor infiltrating lymphocytes in microsatellite stable colon cancer predict outcome to adjuvant active specific immunotherapy

Annelies Turksma,Alfons Van Den Eertwegh,Veerle Coupe,Jeroen Belien,Marc Shamier,Gerrit A Meijer,Vincent De Weger,Kevin Lam,Erik Hooijberg,Chris Meijer

doi:10.1186/2051-1426-3-s2-p405

Abstract

Meeting abstracts To determine the prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in colon cancer in a cohort of patients who previously took part in a trial on adjuvant Active Specific Immunotherapy (ASI). Vermorken et al.[[1][1]] conducted a multicenter clinical trial on

Highlights

Background informationVermorken et al.[1] conducted a multicenter clinical trial on adjuvant Active Specific Immunotherapy (ASI) for colon cancer patients
A comparison was made between surgery alone and surgery followed by adjuvant ASI treatment
The recurrence free interval for patients with stage II tumors was significantly extended for patients treated with surgery plus ASI compared to surgery alone, but not for stage III patients

Summary

Introduction

Background information Vermorken et al.[1] conducted a multicenter clinical trial on adjuvant ASI for colon cancer patients. A vaccine consisting of irradiated autologous tumor cells admixed with the adjuvant Bacillus Calmette-Guérin bacteria has been evaluated. A comparison was made between surgery alone and surgery followed by adjuvant ASI treatment.

Results

Conclusion